Skip to main content

Table 3 Basic characteristics of patients with NHL from the study sample

From: The use of chemotherapy regimens carrying a moderate or high risk of febrile neutropenia and the corresponding management of febrile neutropenia: an expert survey in breast cancer and non-Hodgkin's lymphoma

Basic demographic & clinical characteristics 3-weekly regimens
(n=28)a
Dose dense regimens
(n=11)b
All regimens
(n=39)
Age range (years) 18-64 20-61 18-64
IPI low, n (%) 7 (25) 4 (36) 11 (28)
IPI low/intermediate, n (%) 11 (39) 3 (27) 14 (36)
IPI high/intermediate, n (%) 5 (18) 1 (9) 6 (15)
IPI high, n (%) 5 (18) 3 (27) 8 (21)
Ann Arbor stade III/IV, n (%) 21 (75) 8 (73) 29 (74)
Prior/concomitant radiotherapy, n (%) 2 (7) 0 2 (5)
  1. Basic demographic and clinical characteristics of the patients with NHL are presented for all 3-weekly chemotherapy regimens, for dose-dense regimens (R-ACVBP-14, ACVBP, R-CHOP-14 and R-etoposide, cyclophosphamide), and for all regimens.
  2. a 3-weekly regimens were R-CHOP-21 (n = 13), CHOP-21 (n = 3), BVAM (n = 2), R-DHAP (n = 2), R-GEMOX (n = 2), R-COPADEM (n = 2) and Hyper CVAD, ESHAP, methotrexate/vincristine/ifosfamide/dexamethasone, R-ICE (1 patient each).
  3. b Dose-dense regimens were R-ACVBP-14 (n = 6), ACVBP (n = 2), R-CHOP-14 (n = 2) and R-etoposide-cyclophosphamide (n = 1)